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a  b  s  t  r  a  c  t
Maternal  vaccination  has  been  evaluated  and found  to be  extremely  effective  at preventing  illness  in
pregnant  women  and  new-borns;  however,  uptake  of  such  programmes  has  been  low  in  some  areas.
To  analyse  factors  contributing  to  uptake  of  vaccines  globally,  a  systematic  review  on  vaccine  hesitancy
was  carried  out  by  The  Vaccine  Conﬁdence  Project  in  2012.  In order  to  further  analyse  factors  contribut-
ing  to uptake  of maternal  immunisation,  a  further  search  within  the  broader  systematic  review  was
conducted  using  the  terms  ‘Pregnan*’  or ‘Matern*’.  Forty-two  articles  were  identiﬁed.  Pregnancy-related
articles  were  further  screened  to identify  those  focused  on  concerns,  trust  and  access  issues  regarding
maternal  vaccination  reported  by pregnant  women  and  healthcare  workers.  Thirty-ﬁve  relevant  articles
were  included  which  were  then  searched  using  the snowballing  technique  to identify  additional  rele-
vant  references  cited  in  these  articles.  A  search  alert  was  also conducted  from  February  to April  2015
in  PubMed  to ensure  that no new  relevant  articles  were  missed.  A  total  of  155  relevant  articles  were
included.
Most  of the  literature  which  was  identiﬁed  on  hesitancy  surrounding  vaccination  during  pregnancy
reports  on determinants  of inﬂuenza  vaccine  uptake  in  North  America.  Research  conducted  in  low-income
countries  focused  primarily  on  tetanus  vaccine  acceptance.  The  main  barriers  cited  were  related  to  vaccine
safety,  belief  that vaccine  not  needed  or effective,  not  recommended  by  healthcare  worker,  low  knowl-
edge about  vaacines,  access  issues,  cost, conﬂicting  advice.  From  the  point  of  view  of  healthcare  workers,
barriers  included  inadequate  training,  inadequate  reimbursement  and  increased  workload.  Twenty-seven
out  of  46 (59%)  articles  mentioning  ethnicity  reported  lower  rates  of coverage  among  ethnic  minorities.
Barriers to vaccination  in  pregnancy  are complex  and  vary  depending  on context  and  population.  There
are wide  gaps  in  knowledge  regarding  the  attitudes  of  healthcare  workers  and  how  ethnicity  and  gender
dynamics  inﬂuence  a  pregnant  woman’s  decision  to vaccinate.
© 2015  The  Authors.  Published  by Elsevier  Ltd. This  is an open  access  article  under  the  CC BY  license. Introduction
Over the past two decades, tremendous progress has been
ade in halving worldwide maternal and child deaths, supported
y the drive to meet Millennium Development Goals (MDGs) by
015. One of the targets of UN The Sustainable Development Goals
SDGs) aims to continue this momentum by reducing the global
aternal mortality ratio to less than 70 per 100,000 live births
1].
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264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article u(http://creativecommons.org/licenses/by/4.0/).
Maternal vaccination programmes have been evaluated and
found to be extremely effective at preventing illness in pregnant
women and new-borns [2]. The pertussis vaccine is given as
part of a combined product: diphtheria/tetanus/acellular per-
tussis/inactivated polio vaccine (dTaP/IPV) [3]. Inﬂuenza and
pertussis vaccinations during pregnancy are now offered in many
countries, including Australia, Belgium, Canada, China, France,
Germany, India, Mexico, the Netherlands, Poland, Spain, Slove-
nia, Switzerland, Turkey, the UK and the USA. The monovalent
maternal tetanus vaccination is implemented as part of the rou-
tine immunisation programme in most developing countries.
Group B Streptococcus (GBS), Respiratory Syncytial virus (RSV) and
Cytomegalovirus (CMV) vaccines are also currently being devel-
oped for use in pregnancy.
Pertussis and inﬂuenza are preventable diseases with poten-
tially severe consequences for new-born infants and in the case of
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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nﬂuenza, for pregnant women. Infants under the age of 6 months
re vulnerable to transmission of pertussis and inﬂuenza infection
rom others, especially their mothers. The most common clinical
yndromes due to pertussis, requiring intensive care admission
n infants, are apnoea, pneumonia and seizures. Most deaths are
ssociated with the presence of pneumonia [4].
Over six million children under the age of ﬁve died in 2013 and
ore than half of these deaths were due to conditions that could be
revented or treated with access to simple, affordable interventions
uch as vaccination [5]. Mortality reduction in new-born infants
nder 1 year of age has been gradual, especially in the highest bur-
en countries in Africa [6], declining on average three percent per
ear since 1990 [7]. The relative proportion of new-born deaths
ow accounts for about 44% of the total under-ﬁve mortality and
ew-borns are projected to make up 55% of all under-ﬁve mortal-
ty by 2035 [8]. If the present rate of decline continues, it will be
ver a century before an African new-born baby has the same sur-
ival probability as one born in Europe or North America in 2013 –
hree times longer than this decline took in industrialised countries
efore neonatal intensive care began [6].
Childhood deaths associated with inﬂuenza are most frequent in
nfants under the age of 6 months; inﬂuenza can also cause bacte-
ial pneumonia and otitis media. Maternal inﬂuenza infection has
een associated with an increased risk of hospitalisation relative
o non-pregnant women of the same age: in an analysis of acute
espiratory illness visits within a managed-care organisation, non-
regnant women had ten excess visits per 1000 compared with
3.7 excess visits per 1000 among pregnant women [9].
Inﬂuenza and pertussis vaccine uptake in pregnancy are around
0% [10] and 62.3% [11] respectively in England. However, lower
ptake rates have been reported in some areas of the UK and in
ther countries, due to challenges such as lack of knowledge on the
art of health care workers (HCW) and pregnant women related
o the safety and efﬁcacy of vaccines provided during pregnancy
12], complex delivery arrangements involving different HCW,
hallenges in data collection and reporting [13] and because the
accines were newly introduced. Pregnant women and HCW also
eport feeling confused by mixed messages regarding vaccination
nd medication in pregnancy.
Maternal and neonatal tetanus (MNT) are among the most com-
on  lethal consequences of unclean deliveries and umbilical cord
are practices in many countries [14]. However, on the basis of
ause-of-death trends (2000–2012), tetanus had the largest rela-
ive decrease, of more than two-thirds from 1.3 deaths (per 1000
ive births) to 0.4. This decrease is associated with substantial
ncreases in tetanus toxoid vaccination [15] and may  also relate
o improved cleanliness, cord care practices and education [16].
igh vaccination uptake however, must be sustained as there is no
erd immunity effect against tetanus. Neonatal tetanus is an acute
isease presenting initially with loss of ability to suck, followed by
eneralised rigidity and painful muscle spasms as the disease pro-
resses. Most (90%) cases of neonatal tetanus develop symptoms
uring the ﬁrst 3–14 days of life with the majority presenting at 6–8
ays. Mortality is very high: in the absence of medical treatment,
ase fatality approaches 100% [17].
In terms of new vaccines in the pipeline, preclinical and human
hase I studies of GBS vaccine have been completed demonstrat-
ng the safety and immunogenicity of the vaccine. Phase III vaccine
rials are still needed to determine the clinical efﬁcacy of mater-
al GBS vaccination [18] but acceptability of this vaccine would
e extremely important as women colonised with GBS during
regnancy are at increased risk of premature delivery and peri-
atal transmission of the organism. Amniotic infection can result
n maternal sepsis and very rarely, meningitis [19]. Though there
re very little data on neonatal GBS disease worldwide, studies in3 (2015) 6420–6429 6421
African countries have indicated incidence as high as 1.21 per 1000
live births [20].
Multiple vaccine candidates and at least one second-generation
monoclonal antibody are currently in clinical testing for RSV.
Globally, RSV is responsible for over 30 million new acute lower
respiratory infection episodes in children under ﬁve, resulting in
more than 3.4 million hospital admissions each year. Over 90% of
all RSV-associated deaths are estimated to occur in low and middle-
income countries (LMIC) [21].
With regards to CMV, two different vaccines showed promis-
ing results in phase II clinical trials that studied healthy adults
and immunocompromised solid-organ and bone-marrow trans-
plant recipients, respectively [22].
Some challenges to obtaining high vaccination uptake during
pregnancy are due to “vaccine hesitancy”. Vaccine-hesitant indi-
viduals may  refuse some vaccines, but agree to others or delay
vaccines and are inﬂuenced by a number of factors including issues
of conﬁdence, complacency and convenience/access [23].
The Strategic Advisory Group of Experts (SAGE) on Immunisa-
tion established a Working Group dealing with vaccine hesitancy
in March 2012 [24]. The working group drafted a “Model of deter-
minants of vaccine hesitancy” (Fig. 1) organised around three
key domains: (1) contextual inﬂuences – including historic, socio-
cultural, environmental, health system/institutional, economic or
political factors; (2) individual and group inﬂuences – including
inﬂuences arising from personal perceptions of the vaccine or
inﬂuences of the social/peer environment; and, (3) vaccine and
vaccination-speciﬁc issues which are directly related to the char-
acteristics of the vaccine or the vaccination process (Fig. 1). This
model includes a broad selection of factors that have been identi-
ﬁed as potential inﬂuencers of vaccine hesitancy drawn from the
collective experience and insights of the SAGE WG members [23].
The model has been used in this literature review to categorise
concerns surrounding vaccination during pregnancy.
To address some of these issues, communication strategies
around the safety and effectiveness of the inactivated inﬂuenza and
acellular pertussis vaccines in pregnancy have targeted pregnant
women and HCW in some settings [25,26]. However, a vaccine
hesitancy literature review conducted by The Vaccine Conﬁdence
Project in 2012 found only 42 out of 1164 articles focusing on vacci-
nation during pregnancy and there have only been four systematic
literature reviews conducted on factors associated with vaccina-
tion uptake during pregnancy. All of these reviews focused solely
on the inﬂuenza vaccine. Two  were published in 2010 [27,28], one
in 2011 [29] and one in 2014 (with a search that was  performed
up to November 2013) [30]. The Bulifon et al. [27] article identiﬁed
inﬂuences on decision-making for inﬂuenza A/H1N1v vaccination
among pregnant women. The lack of information on inﬂuenza vac-
cination for pregnant women and confusing information relating
to the risk of adverse foetal events following vaccination were
reported. In France, these concerns led to the vaccine being dis-
credited by the mass media and in the population before it became
available. The Guthmann et al. [28] article focused on reasons for the
low uptake of the inﬂuenza vaccine in all groups in France, including
pregnant women. Bish et al. [31] carried out a systematic litera-
ture review to examine the psychological and demographic factors
associated with uptake of vaccination globally during the 2009 pan-
demic and Yuen et al. [30] carried out a literature review of factors
inﬂuencing uptake of inﬂuenza vaccination during pregnancy in
North America.
With reference to the barriers to vaccination during pregnancy
mentioned above and in the SAGE working Group Model of Deter-
minants of Vaccine Hesitancy, the aim of this literature review
is to analyse factors inﬂuencing uptake of vaccines in pregnancy,
focusing on maternal and HCW concerns, trust and access issues.
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Fig. 1. SAGE Working Group (WG) “Model of determinants of Vaccine Hesitancy”.
Source: Larson et al. [23].
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Table 1
Keywords used in search strategy for literature review on vaccine hesitancy.
Vaccin* OR immunis* OR immuniz*
AND
Anxiety OR doubt* OR trust OR intent* OR dilemma* OR attitude* OR
distrust OR mistrust OR controvers* OR objector* OR awareness OR
dropout* OR Perception* OR misconception* OR uptake OR behavi*r OR
exemption* OR refus* OR misinformation OR barrier* OR belief* OR fear*
OR rejection OR opposition OR choice* OR criticis* OR hesitanc* OR
rumo*r OR delay OR mandatory OR accept* OR concern* OR compulsory
OR knowledge OR conﬁdence OR decision making OR anti-vaccin* OR
parent* con*
Additional limits
• Publication dates (2004–2012)
• Languages (EU only)
Databases
• Mainstream & regional (SR on VH determinants)
•  Mainstream and regional (SR on VH strategies). Methods
.1. Search strategy
To analyse factors leading to uptake of all vaccines globally, a
ystematic review on vaccine hesitancy was carried out by The
accine Conﬁdence Project in 2012 [23]:
.1.1. Systematic review on vaccine hesitancy search strategy
A search strategy was developed in Medline and then adapted
s required by differential indexing across several multidisci-
linary mainstream and regional databases including: Medline,
mbase Classic & Embase, PsychInfo, Cochrane, CINAHL Plus,
eb  of Science, IBSS, LILACS, AfricaWideInfo and IMEMR. Thetrategy included an extensive list of keywords (Table 1) and
elated MeSH/subject headings in an effort to capture the many
imensions and expressions of vaccine conﬁdence, trust and
esitancy.
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Table  2
Inclusion and exclusion criteria.
Inclusion criteria
•  Articles that include research on the following:
◦  Vaccine hesitancy, trust/distrust, perceptions, concerns, conﬁdence,
attitudes, beliefs about vaccines and vaccination programmes (relating
to vaccination in pregnancy) by individuals (pregnant women, HCW) or
communities
Keywords for search by title: (vaccin* OR immuni*) AND (pregnan* OR
maternal)  AND (attitude OR awareness OR access OR predictors OR factors
OR  determinants OR refusal  OR hesitancy OR acceptance)
•  Location: any
• Publication years: any
• Vaccine: vaccines provided during pregnancy (inﬂuenza,
dTaP/IPV/monovalent tetanus vaccine)
• Concerns: all concerns
• Populations: pregnant women, women who  have recently given birth,
HCW
•  Languages: any
•  Vaccines not currently available, such as group B Streptococcus vaccine
Exclusion criteria
•  Not about vaccines provided during pregnancy
•  Non-peer reviewed articles such as editorials, letters,
comment/opinion, pilot studies
•  Research and development
◦ Safety research
◦ Serologic investigations
◦ Immunogenicity studies
◦ Efﬁcacy trials
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3◦  Pre-clinical trial research
◦ Cost-beneﬁt analysis or cost effectiveness trials
In order to analyse factors inﬂuencing uptake of vaccines in
regnancy, a further search was conducted, within the broader sys-
ematic review, using the terms ‘Pregnan*’ or ‘Matern*’. Forty-two
rticles were identiﬁed. The pregnancy-related articles were then
creened to identify those which focused on maternal and HCW
oncerns, trust and access issues regarding vaccination. Thirty-ﬁve
elevant articles were included which were then searched using the
nowballing technique [32] to identify relevant references cited in
hese articles. The snowballing technique was also used on articles
ecommended by peers as well as articles identiﬁed in a PubMed
earch as the original search conducted by the Vaccine Conﬁdence
roject commenced in 2012 and more relevant articles may  have
een published since then.
The PubMed search commenced on 19/02/2015 and ran until
2/04/2015 with the following terms: (vaccin* OR immuni*) AND
pregnan* OR maternal) AND (attitude OR awareness OR access OR
redictors OR factors OR determinants OR refusal OR hesitancy OR
cceptance) (all dates were included).
.2. Study selection
Once retrieved, peer-reviewed articles were screened by title
nd abstract according to a set of inclusion and exclusion criteria
Table 2).
.3. Data analysis
Data was extracted from included articles and analysed in Excel.
. Results
Thirty-eight out of 42 articles were included from the 2012
ystematic literature review [23]. An additional 239 articles were
ound after using the snowballing technique with these articles
Fig. 2). Fourteen articles were added from peer recommenda-
ions and 111 from the additional PubMed search alert. A total of
64 articles were screened by title and abstract. One hundred and3 (2015) 6420–6429 6423
eighty-three articles were excluded by title and abstract, two  were
not available by full text and one was  not able to be translated (from
Hungarian) due to copyright issues relating to the article. One hun-
dred and seventy-eight articles were screened by full text and 61
were excluded by full text, resulting in 117 articles. There were a
total of 155 articles including the relevant articles from the earlier
vaccine hesitancy search (2012) [23]. These articles included 113
focusing on the inﬂuenza vaccine (A(H1N1), seasonal inﬂuenza or
both), 16 on tetanus, seven on dTaP/IPV, two on GBS and 17 on any
vaccine given in pregnancy.
3.1. Main ﬁndings
Almost all of the studies (113/155, 73%) focused on the inﬂuenza
vaccine and of these, 73/113 (65%) were conducted in North Amer-
ica. Studies focusing on the tetanus vaccine were focused mainly in
Asia and Africa (8/16, 50% and 4/16, 25% respectively) (Fig. 3).
There has been an increase in articles focusing on the deter-
minants of inﬂuenza vaccination uptake in pregnancy since 2008,
peaking at 26 articles in 2011. This has since declined to just seven
in 2014 and three as of 21st April 2015. Most articles focusing on
the tetanus vaccine (14/16, 88%) were published between 1990 and
2005 [33–46]. There were very few articles focusing on dTaP/IPV
with the most (4/7, 57%) published in 2014 and 2015 [47–50]
(Fig. 4).
Sample sizes of pregnant women surveyed/interviewed in the
included articles were between 10 and 55,570. Nine articles
reported on the number of women intending to vaccinate.
The main concerns cited in the included articles were regarding
the safety of vaccines in pregnancy (64/155, 41%). Other frequently
cited barriers were: concerns about the efﬁcacy or the belief that the
vaccine is not necessary (28/155, 18%); low knowledge about the
vaccines and/or the diseases they prevent (among both pregnant
women and HCW) (22/155, 14%); no recommendations from HCW
(17/155, 10%); and access/availability issues (6/155, 4%). From the
point of view of the HCW, barriers included inadequate reimburse-
ment [51–53] and training [54] and increased workload [55] (6/155,
4%). Other barriers were conﬂicting advice [56–58], cost [47,59] and
religion [60] (Fig. 5).
When these varied concerns were mapped against the SAGE
Working Group model of determinants of vaccine hesitancy (Fig. 1),
for all vaccines, more than half were grouped under ‘risks/beneﬁts
(perceived/heuristic)’ which includes safety concerns (83/155,
54%). The role of healthcare professionals was  the second biggest
category of issues (26/155, 17%) and included concerns such as no
recommendation from the HCW. Inadequate knowledge of why,
where, what and when vaccines are needed was also a barrier
to vaccination (25/155, 16%). The main concerns regarding the
inﬂuenza, dTaP/IPV and GBS vaccines fell into the ‘risk/beneﬁt
(perceived/heuristic)’ category (mostly regarding the safety of the
vaccine). The main concerns regarding the tetanus vaccine fell into
the ‘knowledge of why/where/what/when vaccines are needed’
category (Fig. 6).
One hundred and eleven out of 155 (72%) articles focused
on attitudes towards vaccination in pregnancy among pregnant
women/women who had recently given birth, 29/155 (19%) on
attitudes of HCW and 15/155 (10%) on the attitudes of both. The
main vaccine of focus was inﬂuenza both groups (i.e. pregnant
women/mothers and HCWs). Articles focusing on attitudes of
HCW were more likely to cite barriers regarding ‘knowledge of
why/where/what/when vaccines are needed’ (7/29, 24%) than
those focusing on pregnant women  (15/111, 14%) (note that these
ﬁgures do not include the articles that focused on both pregnant
women/new mothers and HCW).
These concerns were grouped into larger overarching categories
according to the SAGE Working Group model of determinants
6424 R.J. Wilson et al. / Vaccine 33 (2015) 6420–6429
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Fig. 1). Most concerns fell into the ‘Individual/social group
nﬂuences’ category (106/155, 68%), followed by ‘Vaccine &
accine-speciﬁc issues’ (37/155, 24%) and ‘Contextual issues’
11/155, 7%).
Only 46/155 (30%) articles mentioned ethnicity as a factor inﬂu-
ncing vaccine uptake. Of these, the majority (38/155, 25%) focused
n the inﬂuenza vaccine. Twenty-seven out of 46 (59%) articles
eported lower rates of vaccination coverage among ethnic minori-
ies [42,56,60–83]. Only 8/46 (17%) reported higher uptake rates
mong ethnic minorities and 11/46 (24%) reported no difference.
ne hundred and nine articles (70%) did not mention ethnicity as
 factor related to vaccination uptake.
Five articles found that agreement/advice from the pregnant
oman’s husband/partner signiﬁcantly affected her likelihood to
accinate [44,45,84–86]. In Canada, advice from a spouse was fre-
uently considered important in the immunised group [87]. In thess ﬂow chart.
Ivory Coast, the agreement of the husband is considered neces-
sary because he is the head of the family, the decision maker, and
controls the money [44]. In Pakistan, unmarried females are not
encouraged to get themselves vaccinated [45]. In Turkey, 37.9% of
the study group stated that they made their decisions on their own,
10.5% said their vaccination decisions were made by their spouses
and 51.5% said they decided with their spouses [86] and in the USA,
women cited their partner’s dissuasive role; often due to the latter’s
lack of knowledge or own lower vaccine uptake [84].
The recommendation from a HCW to receive vaccination dur-
ing pregnancy was reported in most articles to increase vaccination
uptake. In a study by Walker et al. [88], it was  found that women
who were offered inﬂuenza vaccination by a HCW were more likely
to be vaccinated (71%) than women who  were not offered the vac-
cine (14%) and they were more likely to have positive attitudes
about vaccine effectiveness and safety.
R.J. Wilson et al. / Vaccine 33 (2015) 6420–6429 6425
Fig. 3. Vaccines mentioned in the literature by country.
Fig. 4. Articles by publication date and vaccine.
Fig. 5. Concerns by vaccine. Note: numbers do not add up to total number of articles as only articles specifying a particular, currently available vaccine were included in this
chart.
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. Discussion
The aim of this literature review was to analyse factors con-
ributing to uptake of vaccines in pregnancy, focusing on the
erspectives of pregnant women and HCW to identify the spectrum
f concerns, trust and access issues.
The largest number of articles focused on the inﬂuenza vaccine
nd the primary focus on the inﬂuenza vaccine was  in North Amer-
ca and most were published in 2011 due to the 2009 A(H1N1)
andemic. The number of articles focusing on the inﬂuenza vac-
ine has since declined and could be because it has now been 6
ears since the last inﬂuenza pandemic.
Articles focusing on the tetanus vaccine were primarily in
esearch on low-income countries and were mostly published
etween 1990 and 2005 [89], reﬂecting the growing momen-
um around tetanus immunisation after WHO  called for neonatal
etanus elimination in 1989 with an initial target of 1995, which
as then extended to 2000. In 1999, the Maternal and Neonatal
etanus Elimination Initiative was launched by UNICEF, WHO  and
NFPA with yet another new target date of 2005 [14], which has
ince been extended to 2015 While there has been considerable
rogress, the extended targets reﬂect some of the challenges that
ere faced.
There were very few articles focusing on dTaP/IPV which could
e due to the relatively recent introduction of the vaccine during
regnancy in some countries. Working Group Model of Determinants.
The main concerns cited in the included articles were related
to the safety of vaccines in pregnancy. However, most studies did
not offer the opportunity for participants to detail what these safety
concerns were. While low knowledge about the vaccines, their efﬁ-
cacy, their availability and the diseases they prevent, were among
the reasons for low vaccine uptake, as some studies reported,
the role of the media regarding pregnant women’s knowledge
about and decisions to vaccinate cannot be ignored [85–87,90–92].
Almost all articles mentioned that recommendations from a HCW
to receive the vaccine had a large impact on vaccination uptake
[88].
When concerns were grouped into larger overarching categories
of the SAGE model of determinants, most concerns fell into the
‘Individual/social group inﬂuences’ category (106/155, 68%). This
demonstrates the extent that a pregnant woman’s social context
and members of the local community, family and friends inﬂuence
her decision to vaccinate. Five articles explicitly stated the hus-
band/partner’s role in the decision to vaccinate but did not analyse
this aspect of vaccination uptake in detail.
Twenty-seven out of 46 (59%) articles reported lower vaccina-
tion uptake among ethnic minorities. One article [80] on Ghana
suggested that women  from ethnic minorities are discriminated
against due to their poor socio-economic position, language bar-
riers that prevent them from understanding and communicating
with HCW, access issues related to their geographical location and
less health education.
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Very few (four) literature reviews were found which focused
n identifying factors associated with vaccination uptake in preg-
ancy. All four reviews focused on the inﬂuenza vaccine and the
iews of pregnant women. Two of the reviews [27,28] focused on
ptake in France.
Most of the literature focused on the views of pregnant women.
nly 29/155 (19%) solely focused on views of the HCW. There is the
eed for more in-depth analysis on the barriers HCW cited to vacci-
ation, including inadequate training, inadequate reimbursement
nd increased workload.
Although West Africa has the highest global burden of whoop-
ng cough thus far in 2015, with 500 cases reported in Liberia
93], the dTaP/IPV vaccine is not yet provided in pregnancy. How-
ver, it must be noted that the reason for the recent outbreak of
ertussis in Liberia could be due to the childhood immunisation
rogramme being affected by the recent Ebola outbreak. As the
urden of pertussis disease was highest in young children [94],
aternal vaccination may  not be the most appropriate strategy.
As of March 2015, maternal and neonatal tetanus is still a pub-
ic health problem in 23 countries, mostly in Africa as well as
fghanistan, Cambodia, Equatorial Guinea, Haiti, India, Indonesia,
raq, Pakistan, Papua New Guinea, Philippines and Yemen [14].
owever, literature on vaccine uptake and reasons for under-
accination is under-reported in low-income countries: research
n the tetanus vaccine was only found in four African countries, as
ell as Bangladesh, India, Indonesia, Pakistan, Peru and Turkey.
A limitation of this literature review was that there was no qual-
ty criteria applied to the selection of papers for inclusion of the
eview, therefore there is no comment on the quality of the studies
eported and this could affect the validity of some of the conclu-
ions. The studies selected were primarily qualitative, and our aim
as to identify the spectrum of concerns and issues identiﬁed in
he literature we found which were expressed by pregnant women
nd health care workers.
. Conclusion
This literature review has shown that both pregnant women
nd HCW cite safety concerns as a main barrier to obtain-
ng/providing inﬂuenza and pertussis vaccines during pregnancy.
owever responses differed depending on geographical area: in
ow-income countries for example, pregnant women were more
ikely to cite access issues as a barrier to vaccination. There are also
ide gaps in knowledge regarding the attitudes of HCW to vaccina-
ion in pregnancy, which is signiﬁcant considering the impact they
ave on a woman’s decision to vaccinate.
From the supply side, regulatory agencies still do not have a
icensing pathway for many vaccines for pregnant women, manu-
acturers remain concerned about liability and providers perceive
hat pregnant women are unwilling to accept vaccines [95].
As the MDG  era comes to an end, the development agenda
eyond 2015 is widening to include other important health issues
uch as non-communicable diseases (NCDs). However, neither still-
irths nor neonatal deaths are mentioned in post-2015 documents
96] risking that the current momentum for new-born health may
e lost.
Barriers to vaccination in pregnancy are complex and can differ
rom barriers and concerns affecting uptake of routine childhood
accinations. Maternal vaccination is administered at a time when
he patient is cautious about various behaviours, including tak-
ng medications and vaccinations, and feels responsible for not
ust her own life but of that foetus. Depending on the cultural
ontext, different norms are also established around the time of
regnancy. Barriers also vary depending on context and target
opulation.
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Taking these points into account, ‘quick-ﬁx’ interventions which
aim to increase vaccination uptake, such as health communication
messages and training physicians in communication strategies [97],
without understanding addressing the root cause of vaccine hesi-
tancy in speciﬁc contexts, are likely to have little effect on patients’
decisions to vaccinate or on the provider’s own conﬁdence in com-
municating with parents about vaccines.
It is important to understand how cultural and gender dynamics
in different settings can inﬂuence a woman’s decision to vac-
cinate. This can be done through in-depth local ethnographies,
taking the views of all community members and inﬂuencers into
account, complemented by in-depth individual interviews and
focus groups. Research could also examine some of the complex
socio-political reasons for under-vaccination in certain commu-
nities must to inform vaccination policies and delivery strategies.
With more understanding of the perspectives of pregnant women,
their providers and communities, maternal vaccine strategies will
be more likely to reach and protect pregnant women and their
newborns from preventable disease.
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